Understanding patients' perspective in the use of generic antiepileptic drugs: compelling lessons for physicians to improve physician/patient communication by Kore Liow
BioMed CentralBMC Neurology
ssOpen AcceDebate
Understanding patients' perspective in the use of generic 
antiepileptic drugs: compelling lessons for physicians to improve 
physician/patient communication
Kore Liow
Address: Via Christi Comprehensive Epilepsy Center, University of Kansas School of Medicine at Wichita, 848 N St Francis, 3950 Wichita, KS 
67214, USA
Email: Kore Liow - kliow@kumc.edu
Abstract
Background: Epilepsy is a condition in which consistency of treatment is paramount to successful
management and for most patients, effective seizure control can be achieved. Given the severe
consequences of even a single breakthrough seizure, patients should be afforded every opportunity
to succeed on their given regimens.
Discussion: Some experts argue that global policy on generic antiepileptic drug substitution in
epilepsy should be limited – occurring at the discretion of and with careful monitoring by the
physician. While the debate continues, physicians still have daily responsibilities to their patients to
help them best manage their epilepsy within the context of the current environment – the reality
of which may involve switching to a generic antiepileptic drug or navigating various formulations
between generics.
Summary: To provide context, this paper first reviews the main "hot button" issues fueling the
ongoing generic debate, including a broad overview of the current state of the literature. The main
goal however is to provide physicians with a patient perspective on generic antiepileptic drug use
in epilepsy as a source of clinically useful, everyday advice to improve communication and increase
patient self-advocacy, both of which are necessary for optimal patient outcome.
Background
Due to increasing healthcare costs, it is increasingly com-
mon and beneficial for patients to switch to generic med-
ications. [1,2] The switch for patients with chronic
diseases like hypertension and hyperlipidemia could
result in cost savings, but epilepsy is different from many
other chronic conditions in that it typically responds to
treatment in an "all or nothing" manner. Many patients
with epilepsy could do well with generic medications, but
for other patients, the switch could be devastating. Even a
single breakthrough seizure could put the patient at
immediate risk for injury, loss of income, driving privi-
leges, or death. [3] Cost-savings gained from lower pre-
scription drug costs may be lost after accounting for
emergency room visits or hospitalization, not to mention
the personal costs incurred by patients suffering break-
through seizures. [4,5]
Many newer generation antiepileptic drugs (AEDs) have
recently lost patent protection or soon will, serving to fur-
ther fuel the ongoing debate over the risk/benefit profile
of generic substitution in epilepsy treatment. For over 20
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small retrospective analyses and survey results raising con-
cerns about the interchangeability of generic antiepileptic
drugs (AEDs) with their branded counterparts in the treat-
ment of epilepsy has been gathering in the scientific liter-
ature. Although overall these reports lack scientific rigor,
many neurologists and epileptologists remain concerned
that many countries' current bioequivalence standards are
inadequate in epilepsy given the reports of breakthrough
seizures after a treatment change. [6-10] Furthermore, per-
sons with epilepsy may exhibit a natural wariness toward
any treatment switch especially when the mantra of "con-
sistency of treatment" is a familiar goal in trying to achieve
and maintain seizure control.
The debate of branded vs generic AEDs will continue until
well-controlled studies evaluate the causative relationship
between generic substitution and increased risk to
patients (either through the occurrence of breakthrough
seizures or increased toxicity). This discussion will first
provide a brief overview of the factors fueling the ongoing
debate including a top-level review of the scientific litera-
ture. With the understanding that this debate is likely to
continue for some time, the overall objective of this paper
is to provide practical "in the clinic" advice to implement
in daily interaction with your epilepsy patients. These rec-
ommendations are based upon a patient forum in which
the goal was to identify ways to improve communication
between patient, physician and pharmacist and to
develop patient self-advocacy, a realization benefitting
both patient and physician.
Discussion
Fueling the Debate
Bioequivalence Versus Therapeutic Equivalence
In the United States and the European Union, approval of
a generic formulation of a drug requires a comparison of
the generic form with the corresponding brand drug in
small crossover trials in several dozen healthy volunteers
(a minimum of 12 are required for European Medicines
Agency [EMEA] guidelines). [11-13] Bioequivalence is
established through a comparison of the rate of absorp-
tion (peak plasma concentration [Cmax] and area under
the plasma concentration-time curve [AUC]. The criteria
set forth require that the 90% confidence interval of the
ratio of the generic to the branded reference compound
for the pharmacokinetic parameters mentioned above fall
within an acceptance range of 80% to 125%. If a generic
drug is deemed to be bioequivalent and has the same
active ingredient as the branded drug with the same dose
availability and routes of administration, the drug is
approved as therapeutically equivalent and substitution is
allowed without risk of toxicity or diminished efficacy.
This standard for evaluating bioequivalence has a number
of critics who are quick to point out that these bioequiva-
lence studies are typically conducted with single doses on
a relatively small number of healthy, young, male volun-
teers. [14] In "real life," generic preparations will be given
to elderly and pediatric patients (a substantial portion of
the epilepsy patient population) as well as those taking a
number of other medications and potentially with con-
comitant conditions. In addition, the boundaries of
"acceptable" variability may be tested when considering
that often numerous versions of a generic product are on
the market, raising the possibility of receiving one drug at
the top of the "acceptable" range and then being switched
without notification to a second generic that was
approved at the bottom of the "acceptable" range. [14] In
direct response to these concerns, the Danish Medicines
Agency narrowed their definition of acceptable bioequiv-
alence for a select group of generics, including AEDs, to
fall within a 90% to 111% range of the reference com-
pound. [15,16] Further complicating the situation,
regardless of the exact definition of bioequivalence, is the
reality that individual patient differences can lead to ther-
apeutic nonequivalence. Indeed, a recently published
study of nine outpatients in Denmark who had reported
problems following a change in the preparation of lamo-
trigine found that, even with the narrower bioequivalence
requirements for mandatory substitution in Denmark,
some patients experienced serious clinical consequences
(eg, relapse of seizures) in association with a change in
preparation that corresponded to significant alterations in
plasma levels. [17] Though these results may be biased
due to the retrospective nature of the study, they do
underscore the problems that can occur with AED formu-
lation shifts due to individual patient differences. Finally,
though beyond the scope of this paper, another broad cat-
egory perpetuating the debate is the ongoing discussion of
the role that individual drug characteristics may play in
establishing true bioequivalence (eg, those drugs with a
narrow therapeutic range, nonlinear kinetics, or those in
extended release formulations). [18]
Challenging the status quo
Regulating agencies contend that bioequivalence estab-
lishes therapeutic equivalence; however this stance is in
contrast to several published accounts of breakthrough
seizures and increased toxicity upon switching to or
between generic formulations. [3,7,19-22] The disparity
between government policy and what physicians and
patients may be experiencing "in the real clinical sce-
nario" has led to many calls to action within the literature.
[12,19,23-26] as well as to the development of position
statements by scientific and medical organizations. [27-
29] The most recently published position statement on
the coverage of anticonvulsant drugs for the treatment of
epilepsy issued by the American Academy of Neurology
(AAN) states unequivocally that the AAN "opposes
generic substitution of anticonvulsant drugs for the treat-
ment of epilepsy without the attending physiciansPage 2 of 10
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rize that the use of newer generation AEDs should not be
limited (eg, through "fail first" policies or high co-pays).
The AAN position statement also lays out the rationale for
its opposition of prior authorization requirements by pri-
vate and public formularies, namely that it is one method
formularies may use to limit access to AEDs. The position
taken by the AAN is consistent with guidelines prepared
by other governing agencies as well, though, as will be
explored later, there are regional differences.
The purpose of these and other recommendations is not
to disparage all generic use. In fact, generic use in de novo
patients or when monitored carefully following a treat-
ment switch can be an important cost-saving measure and
may often occur with success. Rather, at the heart of these
recommendations is the goal of continuity of care for epi-
lepsy patients, a core principle in managing this disease.
Epilepsy is a condition that is controllable, and patients
should be given every chance to succeed with their treat-
ment regimens. Patients not receiving optimal care are at
risk for breakthrough seizures, the consequences of which
can be severe as well as costly (financially and emotion-
ally), including driving accidents, loss of work, increased
emergency room visits and diminished quality of life.
[5,14,28,30]
Strength of the Literature
Published reports of breakthrough seizures accompany-
ing a switch to a generic AED formulation begin to appear
in the literature as far back as the 1980s. [21,31] Early
published reports of double-blind cross-over studies such
as those by Hartley et al (N = 23 children), Oles et al (N =
40) and Mikati et al (N = 10) attempted to more rigor-
ously evaluate the potential risk of a treatment switch in
epilepsy. [20,32,33] Even though these studies did not
identify decreased efficacy following a treatment switch,
the ability to generalize these and other crossover study
results to widespread generic policy is difficult given that
different drugs were evaluated, overall patient numbers
were low, and no consistent effect on serum levels was
observed.
In spite of these studies and a continued presence of this
issue in the scientific literature over an extended period of
time, evidence-based conclusions on the appropriateness
of generic AED substitution have been hampered by a lack
of rigorous, well-controlled studies. To evaluate what has
been most recently published, a Medline search was con-
ducted using search terms "epilepsy" and "generic," and
limited to English language publications from the last 5
years. After eliminating irrelevant articles, the search
revealed 4 claims studies, 4 economical analyses, 16
reviews/opinion pieces, 4 serum level studies, and 6 sur-
veys. Similar to the profile of the publications over the
past two decades, most of these publications supported
the limitation of generic substitution in epilepsy treat-
ment, yet for the most part these were uncontrolled obser-
vations. Two of the more compelling studies most
recently published (Le Lorier 2008, N = 671 and Ander-
mann 2007, N = 1354) evaluated medical/pharmacy
claims data to compare rates of switchback among users of
AEDs compared to other therapeutic areas. In both stud-
ies, a higher propensity to switch back to branded medica-
tions was observed for AEDs compared to other
therapeutic classes. [24,34] In addition, both of these
studies showed a statistically significant increase in AED
dose for those patients not switching back.
As a whole, the data within the scientific literature are
insufficient to support policy changes in that rigorous,
well-controlled studies are lacking; however, they do serve
to convey the long-held concerns shared by physicians
and patients regarding the connection between the use of
generic AEDs and the occurrence of breakthrough sei-
zures. These data also underscore the need for further
study and a definitive examination of cost benefit in epi-
lepsy. One of the biggest advantages to generic drug use is
the short-term cost-savings it affords; however, while the
switch to generic AEDs may be successful and cost effec-
tive in most patients, effective seizure control cannot be
sacrificed based solely upon financial considerations. It
remains unclear if short-term cost savings are sustained
after accounting for the occurrence of breakthrough sei-
zures and/or increased toxicity that may accompany
generic substitution in individual patients. [4]
Physicians have daily responsibilities to their patients to
help them best manage their epilepsy within the context
of the current environment – the reality of which may
involve switching to a generic drug or navigating various
formulations between generics. In order to truly effect
change, we must start with our own patients by improving
communication and providing them with the necessary
tools in order to self-advocate. The following section pro-
vides useful insight and suggested tips for the physician to
pass along to his or her patient based upon feedback from
those who should know best – our patients.
The Patient Perspective
In a physician-moderated patient forum held March 30,
2008, in Washington, D.C., 20 epilepsy patients and car-
egivers shared perspectives, anecdotes, and advice on the
challenges they have faced and continue to navigate in
their attempt to best manage their seizure control with
AEDs. It should be noted that participants were active
members in the U.S.-based and industry-sponsored Epi-
lepsy Advocate program and therefore do not necessarily
represent an equal sampling of the epilepsy patient popu-
lation; however, the content of their discussion revealedPage 3 of 10
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epilepsy everywhere as well as the need for improved
communication with our patients.
My objective therefore was to provide patient insights to
physicians to help improve the level of care. The most sali-
ent features of the sections below are organized by levels
of patient interaction. Due to the fact that patients partic-
ipating in the forum are in the US, some of the specific rec-
ommendations may only apply to a US patient
population and are so noted. Because the main goal of
this paper is to provide physicians with the tools necessary
to help improve the lives of their epilepsy patients, the
discussion points are further noted in a patient/physician
communication tip sheet (Table 1).
Communicating Practical Advice to Your Patient
Level 1: Patient/Physician Relationship
Optimum epilepsy treatment begins at the most basic of
the relationships: the patient and their physician. Indeed,
only through the establishment of good communication
between these two parties can self-advocacy be attained.
To that end, there are many important facts that patients
need to be informed of that affect their ability to best
assist in their own individual treatment management.
Challenges
Given the multitude of newer and older antiepileptics
used as primary and adjunctive therapy – both in brand
and generic formulations – it becomes even more impor-
tant and perhaps confusing for the epileptic patient to
understand the reasoning behind their physician's selec-
tion of treatment. It is paramount that a physician dis-
cusses his/her rationale with the patient in terms of AED
selection and the possible side effects and symptoms of
over/under treatment, thus empowering their patient to
become a partner in the management of their epilepsy
with the goal of a positive treatment outcome.
Studies suggest that patients who engage in open dialogue
with their physician tend adhere to their AED regimen.
[35-38] Therefore it is advised that physicians stress the
importance of patient compliance and drug adherence to
patients and caregivers as it is paramount to treatment
success whether they are taking brand, generics, old or
new AEDs.
Tell your patient
It is important your patient understand the treatment
selected and the expectations you have for this treatment
in terms of attempting to effectively manage their epilepsy
seizure-free, particularly in the context of possible intro-
duction of generic substitution.
Table 1: Patient/Physician Communication Tip Sheet: Improving Patient Experience with Generic AEDs
Discuss with your physician whether you are a suitable candidate for AED substitution or may be at risk for seizure breakthrough.
Learn the typical signs of over and under treatment with your AED or a substituted agent:
• Over treatment
- Dizziness, sedation, rash
• Under treatment
- Breakthrough seizures, auras
Honesty is the best policy! Accurately report dosing history, including missed doses, to your physician and any associated side effects or 
breakthrough seizures. To assist with this effort, keep a diary to record seizures and side effects.
If possible, frequent the same pharmacy to fill your prescriptions and become familiar or friendly with the neighborhood pharmacist.
"Know your pills" whether branded or generic versions – the size, the color – and inspect your medication and its label before leaving the 
pharmacy. Ask questions, if necessary!
Per the "Patient's Bill of Rights," know you have a right to receive the medication you expect to receive; if you have been given a medication 
(i.e., generic substitution) that is not what you expected and you feel uncomfortable accepting, it is within your right to purchase the exact pills you 
have been taking. Buy just one pill if necessary to make it through to your next dose and give yourself time to consult your physician.
Learn the details of your insurance policy. If it has been determined by your physician that you remain on a branded drug not covered by your 
policy, it is your right to request the drug be approved and added, and if necessary, appeal a decision if request is initially rejected.
Learn your state's laws regarding generic substitution and "DAW" prescriptions, and if necessary, call your legislator or write a letter to 
your congressperson in cases where you feel state laws must either be enacted or changed. (Visit http://www.epilepsy.com for more information 
about state laws governing AEDs.)
Inform your doctor of side effects and breakthrough seizures following AED substitution and ask that they be reported to MedWatch, the 
FDA's safety information and adverse event reporting program. (For information, call 1-800-FDA-1088 or visit the web site at http://www.fda.gov/
medwatch.)Page 4 of 10
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come off patent, or soon will, and the increasing possibil-
ity in the patient's future of generic substitution either by
way of mandatory requirement or voluntary selection, the
patient must be able to recognize the typical warning signs
of over/under treatment of AEDs.
While many epileptic patients are knowledgeable about
the typical side effects of the drugs themselves, they may
not be able to recognize at first glance the effects of over/
under treatment. For example, dizziness and sedation are
two possible signs of over treatment, while having break-
through seizures or auras could be signs of under treat-
ment. [39,40]
It is within the context of the issue of physician and
patient communication that compliance and adherence
must be discussed. Indeed, as like recognizing over/under
treatment, compliance – or lack thereof – strongly affects
a patient's success in terms of optimum treatment and can
undermine the critical physician/patient relationship.
To effectively discuss compliance and adherence some
physicians may need to reevaluate their patient communi-
cation. In a recent AED adherence survey of epilepsy
patients and physicians, 31% of physicians believed that
they "spend a lot of time talking with their patients about
epilepsy," whereas only 14% of patients agreed with that
statement. Additionally, patients who reported a trusting
relationship with their physician were more likely to be
adherent and willing to discuss missed doses. [41]
From the patient's standpoint, an informal industry-spon-
sored internet-based survey of 451 epilepsy patients
found that patients oftentimes fail to report non-compli-
ance to their doctors. Although 71% of patients agreed
that missing a dose of their AED – be it branded or generic
– is a serious issue and can lead to seizure, only 41% of
patients reported that they immediately take the dose
upon remembering. (To note, 37% of patients who
reportedly missed a dose had at least one breakthrough
seizure, of which 38% required a visit to the emergency
room.) Further, 43% did not inform their physician
immediately that they had missed a dose, and 41% waited
until their next appointment to do so. [42]
It is important for physicians to tell their patients that
"honesty is the best policy." It is imperative that a patient
or caregiver accurately report to their physician dosing his-
tory, including missed doses, in an appropriate time-
frame. For the physician's part, you must remember that
in an effort to empower your patient to be your ally in
their treatment and optimum health, they should keep a
seizure diary and learn to trust that their communication
of missed doses or lack of drug adherence will serve to
strengthen your partnership and that the result will be a
better, more honest base on which to build and improve
the patient's quality of life in their effort to remain sei-
zure-free be it through use of generic or branded AEDs.
Keeping Your Patient Safe
Level 2: Patient/Pharmacy Interaction
Given the sheer number of prescription drugs available –
both in brand and generic form – which is growing every
day, it is has become increasingly important for patients
to be aware of policy issues and everyday examples of safe
practices relating to their interactions at the pharmacy
level.
Challenges
Further complicating the issue is that any given generic
may have many different manufacturers. (For example, 17
different generic versions of zonisamide are availa-
ble.)[12] Each of these generics will have unique formula-
tion differences; for pharmacists, this means a
continuously changing pool of medications – both
branded and generic – and manufacturers depending on
current contractual agreements.
Finally, treatment decisions can potentially be impacted
by pharmacy as use of generics and preparation shifts in
the treatment of newly diagnosed patients who continu-
ally experience breakthrough seizures could lead physi-
cians to erroneous assumption that a patient's seizures are
resistant to drug. [43]
Tell your patient
As a physician, it is important to tell your patient that
when he/she walks through the door of their local phar-
macy or calls in their AED prescription refill request, there
are several ways in which they may help manage their
treatment and ensure their needs are best being met, par-
ticularly given the increased potential for generic substitu-
tion at some point in a patient's life.
First, it is imperative for the patient to attempt to establish
a trusting and honest relationship with their pharmacist.
Advise your patient to, if possible, frequent the same phar-
macy to fill their prescriptions and become familiar or
friendly with their neighborhood pharmacist. "I think it's
crucial that you know your pharmacist and they get to
know you and let them know your story, especially when
it's as critical as epilepsy."[44]
Second, physicians must advise their patients to "know
your pills" (or liquid medication). To best ensure safety,
patients must make a point of knowing what each of their
medications looks like whether branded or generic ver-
sions – the size, the color – and always double-check the
label to confirm accurate patient name and address, pre-Page 5 of 10
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instructions, etc. "I open the bag right at the pharmacy
and take a close look at them and if those aren't the pills
I've been taking, I flat-out refuse them."[44]
U.S. physicians also should make their patients aware of
the "Patient's Bill of Rights," which states in effect that a
patient has the right to make sure that they are getting the
medication that they expect to get. [45]
And if for some reason (i.e., generic substitution) your
patient has been given a medication that is not what they
expected or typically receive – and feels uncomfortable
accepting, the patient should know that it is medically
advisable and perfectly within their right to purchase the
pills they have been taking, even if in a low quantity. This
will allow the patient to meet their dosing schedule for a
few days in order to provide enough time to be able to fol-
low up with their physician. Indeed, patients must know
it is acceptable to buy just one pill if necessary to make it
through to their next dose and give them time to consult
their physician.
Lastly, the patient may wish to check with their healthcare
provider in order to inquire as to how many days must
transpire between refill orders; knowing this, for instance,
will help the physician, patient, and pharmacy manage
and sustain an adequate supply of their AEDs by request-
ing refills with enough time available to sustain a supply
delay in the instance their medication is out of stock and
the pharmacy needs to order. [44]
Appreciating a Patient's Residence
Level 3: Regional Differences
Health care systems vary greatly from country-to-country,
as well as state-to-state in the U.S., but the one thing they
have in common is that they are under increased pressure
to control the costs of prescription drugs and other serv-
ices, which has prompted efforts to strongly "encourage or
mandate the substitution of medications with generic
preparations."[13]
Further complicating the issue is the fact that private
insurance companies and public health services have var-
ying and unequal coverage. In the U.S., laws governing
generic substitution vary by state and apply regardless of
whether a patient's payment is through a public insurer
(i.e., Medicaid) or a private insurance company. [46] As
each of the states carries its own set of rules and regula-
tions thus adding to the confusion, it is, therefore, imper-
ative for patients to understand and appreciate the role
that residence plays in their "continuity of care" (Table 2).
Challenges
In regions where generic substitution in mandated, physi-
cians may have to "jump through extra hoops" to ensure
their patients receive the brand drug, if so prescribed. In
the U.S., all states have laws requiring that brand drugs be
dispensed if so ordered by a prescribing physician, but
most states allow pharmacists to make a generic substitu-
tion if a prescription is not specifically marked "dispense
as written" (DAW). Further, in more than a dozen states,
generic substitution is mandated unless a physician spe-
cifically marks a script "DAW," and in four states generic
substitution is mandated without requiring patient notifi-
cation. [47-49]
Differing regional laws that govern pharmacy mandates
and requirements makes it difficult for all parties
involved, and further underscores the importance of good
communication between physicians and their patients.
Tell your patient
First, you must relay to your patient how important it is to
know their insurance plan, whether private or public.
Having knowledge of their healthcare policy will allow
the patient to be best able to communicate their coverage
accurately and effectively as to how it may relate to their
AED treatment.
In terms of the potential for generic substitution, if a phy-
sician has determined that it is imperative for their patient
to remain on a branded drug to help increase likelihood
of seizure-free status, the patient must know that it is not
only well within their right, but also their obligation to
advocate for the AED of their choice.
In some instances, it may require a patient to work with
their physician to draft a letter or letters to their private
insurance company or national healthcare provider
requesting that a particular drug be approved and added
to their policy's coverage. In these cases, it is beneficial for
your patient to know their provider's process and timeline
as each insurer may have slight differences in process.
In addition, it is important for a patient to understand
that such a request can sometimes be accompanied by a
battle that ultimately is well worth waging. A patient must
be prepared to appeal an initial decision and demand that
their case be heard before a Review Board should the
insurance provider deny the first request.
For patients with private insurance, the entire appeals
process will likely take more than submitting a single let-
ter, and oftentimes many patients give up on the process
prematurely. For example, in the U.S., 67 percent of
appeals that are denied the first time never get presented
another time. Physicians must encourage their patients to
exhaust all levels of appeal. Even if an appeal is ultimately
denied, the insurance company could reverse its decision
years later and retroactively cover the costs. [50]Page 6 of 10
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itive studies on generic versus branded AEDs has created
an environment where physicians, patients, and pharma-
cists are functioning without a global standardized set of
guidelines. Unfortunately, this can also lead to even more
confusing regional differences. For example, 40 U.S.
states, legislatures are considering laws that would require
pharmacists to contact a physician to substitute a generic
epilepsy drug, regardless of whether it was marked DAW
or not. Further, legislators in 18 states are considering laws
that would ban generic substitution for epilepsy drugs.
[46]
In all cases, physicians must make clear to their patients
that decisions related to their drug treatment should be
made on a case-by-case basis with their personal well-
being first and foremost in mind. Mandatory generic sub-
stitution is just as objectionable for pharmacy as is legisla-
tion to restrict generic substitution. [50]
A View from the Top
Level 4: The National/International Climate
In order for patients to gain a complete understanding of
the "big picture," physicians must communicate to their
patients the impact of national policy and economic con-
siderations and how these may affect the patient's own
individual care.
Challenges
Despite the fact that the issue of generic substitution of
AEDs is being increasingly highlighted in the scientific lit-
erature and medical field, the possible ramifications,
national and international reporting efforts, and pharma-
coeconomic analyses may not be widely known at the
community level.
Tell your patient
In an effort to empower patients towards self-advocacy,
physicians are advised to make their patients aware of the
following considerations.
First, it is absolutely necessary for patients to report any
breakthrough seizures or side effects following AED sub-
stitution to their physicians. U.S. physicians can and
should report these side effects and any adverse events to
MedWatch, the FDA's safety information and adverse
event reporting program, a process which takes 20 to 40
minutes. (For information, call 1-800-FDA-1088 or visit
the web site at http://www.fda.gov/medwatch.)
Alarmingly, despite the fact that 65% of physicians have
cared for patients with breakthrough seizures as a result of
switching from branded to a generic agent, this finding is
not reflected in the scientific literature or MedWatch. [12]
Table 2: Drug-Substitution Laws Applicable to U.S. Patients
Type of Law States and Territories
Mandatory/permissive substitution:
States generally either permit or mandate that the pharmacist substitute 
a generic version of a prescribed drug if all prescription requirements 
are met.
Mandatory: FL, KY, MA, MN, MS, NJ, NY, PA, PR, RI, WA, WV
Permissive: AL, AK, AZ, AR, CA, CO, CT, DE, DC, GA, GU, HI, ID, 
IL, IN, IA, KS, LA, ME, MD, MI, MO, MT, NE, NV, NH, NM, NC, ND, 
OH, OR, SC, SD, TN, TX, UT, VT, VA, WI, WY
State Drug Formulary: Some states provide a positive (drugs are 
equivalent and interchangeable) or a negative (drugs are not equivalent 
and not interchangeable) formulary to guide appropriate substitution.
Positive: DE, DC, FL, HI, IL, MA, NE, NV, NH, NJ, NY, TN, UT, VA, 
WI,
Negative: AR, KY, MN, MO, NC
Patient consent/notification requirement: Most states require 
patient consent for, or notification of, substitution.
Required: AK, AZ, CA, CO, CT, DE, DC, FL, GA, HI, ID, IL, IN, IA, KS, 
KY, ME, MD, MI, MN, MS, MO, MT, NE, NV, NH, NY, ND, OH, PA, PR, 
SC, SD, TX, UT, VT, VA, WV, WI, WY
Not Required: AL, AR, GU, LA, MA, NJ, NM, NC, OR, RI, TN, WA
Cost savings requirement: Most sates require that the drug 
dispensed be less or no more expensive than the drug prescribed and 
that some of the cost savings be passed on to the purchaser.
Less or no more expensive: AK, AR, CA, DC, GA, GU, HI, ID, IL, 
KS, KY, ME, MD, MA, MS, MO, NV, NH, NJ, NY, NC, ND, OH, OR, PA, 
PR, RI, TN, TX, VT, VA, WI, WY
Savings passed on: CO, CT, DE, FL, IN, IA, ME, MD, MI, MN, MT, NE, 
NM, RI, TN, WA, WV
Requirement not mentioned: AL, AZ, LA, ME, PR SC, SD, UT
NTI drugs recognized as special category Recognizes NTI: KY, NC, PA, SC, TN
Boldface states and territories = mandatory generics substitution without patient consent/notification
Underlined states and territories = permissive generics substitution without patient consent/notification
NTI: narrow therapeutic index
Adapted from [47-49]Page 7 of 10
(page number not for citation purposes)
BMC Neurology 2009, 9:11 http://www.biomedcentral.com/1471-2377/9/11Physicians who care for patients who have breakthrough
seizures or side effects related to generic substitution
should make every effort to obtain complete data, includ-
ing: AED blood level at the time of the breakthrough sei-
zure or side effect; a corresponding AED blood level
(preferably at the same time of day, in the same clinical
laboratory) once the patient is again stable on the brand
or initial generic AED; detailed confirmation of compli-
ance; rechallenge with the substituted generic AED at a
future time (if the patient is willing). [12] After at least five
half-lives a blood level at the corresponding time should
be obtained. Then the patient should return to the base-
line preparation to minimize the chance of a second
breakthrough seizure or side effect. [12]
Moreover, a patient must know that they may feel a slight
difference day-to-day with varying medications, not only
when switched from branded drug to generic, but also
from one generic to another, and it is imperative they
notify their physician to report such side effects.
Lastly, more accurate reporting in the clinical setting may
impact and lead to a better understanding of the pharma-
coeconomic literature. To date, recent economic models
have suggested that short-term savings realized by generic
substitution may be erased by rising costs elsewhere. [2]
Therefore, it is necessary for all parties involved to appre-
ciate the associated real or potential costs associated with
a treatment switch (i.e., monitoring plasma levels and the
cost of managing loss of seizure control). [2,10,51] The
economic cost of poorly controlled epilepsy is enormous,
and the most cost-effective intervention is an AED that
provides total seizure control. [5]
Of course, balance will vary between different AEDs and
different countries and may not always favor use of gener-
ics. For example, a pharmacoeconomic modeling study
performed in Spain demonstrated that if 9% of patients
with epilepsy taking brand-name carbamazepine were
switched to a generic, this would not be cost-effective. The
annual individual patient cost would rise by 38 as com-
pared with treating these patients with brand-name car-
bamazepine, and overall spending on health care in the
country would increase by 2,748,000, principally due to
increased spending on consultations and hospitalizations
for loss of seizure control. [51]
In another example, a questionnaire-based survey of neu-
rologists in the United States also provided clues to the
cost effectiveness of generic AED switching. Of a total
sample of 301 neurologists, 81.4% observed an increase
in the frequency of seizures (67.8%) or adverse events
(56.0%) after patients switched from a branded drug to a
generic version. This necessitated more consultations,
emergency room treatment, and hospitalizations, result-
ing in an additional incremental cost of US $675,004,
mainly from the cost of hospitalizations. This incremental
cost offset to a large extent the savings derived from use of
a less expensive generic. [10]
To reiterate, what may be considered by some as a savings
now (i.e., generic), may lead to paying later (i.e., hospital-
ization for treatment associated with breakthrough sei-
zure, toxic side effects).
"If they could just think of it this way: Switching from a
brand to a generic may save $50 per month, but one hos-
pitalization due to a seizure breakthrough may cost
$4,000–$6,000....and that'd take decades to recoup."[44]
Summary
Given the devastating consequences of even a single
breakthrough seizure on the quality of life of epilepsy
patients, it is crucial that physicians treating epilepsy
patients begin to educate and engage patients in discus-
sion in regards to the use of generic antiepileptic drugs. It
is equally important for physicians and patients to ensure
that there is "continuity of care" of the same medications
that have been controlling their seizures.
Furthermore, should a switch in their antiepileptic medi-
cation be made, whether from brand to generic or one
form of generic to another, it must be done so in a safe
manner, i.e. with the full consent and knowledge of both
the physician and patient to ensure that any sign of over
or under treatment can be promptly identified and correc-
tive action taken. Finally, physicians and patients alike
must be aware that only through improved communica-
tion and increased patient self-advocacy can optimal
patient outcome be realized.
Abbreviations
AEDs: antiepileptic drugs; EMEA: European Medicines
Agency; Cmax: peak plasma concentration; AUC: area
under the plasma concentration-time curve; AAN: Ameri-
can Academy of Neurology; DAW: dispense as written.
Competing interests
Dr. Liow has received research grant/support from
National Institutes of Health, Centers for Disease Control,
NeuroPace, Inc., Johnson & Johnson, Schwarz Bio-
sciences, Inc., Eisai, Inc., UCB, Inc., GlaxoSmithKline, and
Ortho-McNeil Pharmaceutical, Inc. He also has received
consulting and speaker's bureau fees and honoraria from
Pfizer Inc and UCB, Inc.
Authors' contributions
KL Moderated the patient forum, drafted the manuscript,
read and approved the final manuscriptPage 8 of 10
(page number not for citation purposes)
BMC Neurology 2009, 9:11 http://www.biomedcentral.com/1471-2377/9/11Acknowledgements
The patient forum was sponsored by UCB, Inc., and I would like to extend 
a special thanks to the patient participants who contributed to the open dia-
logue.
Also, I gratefully acknowledge the editorial assistance of LeAnn Berens, 
Apurva Dave, PhD, and Jennifer Hepker, PhD, of Prescott Medical Commu-
nications Group in the preparation of this manuscript.
References
1. Duh MS, Andermann F, Paradis PE, Weiner J, Manjunath R, Cremieux
PY: The economic consequences of generic substitution for
antiepileptic drugs in a public payer setting: the case of lamo-
trigine.  Dis Manag 2007, 10(4):216-225.
2. Kramer G, Biraben A, Carreno M, Guekht A, de Haan GJ, Jedrzejczak
J, Josephs D, van Rijckevorsel K, Zaccara G: Current approaches
to the use of generic antiepileptic drugs.  Epilepsy Behav 2007,
11(1):46-52.
3. Heaney DC, Sander JW: Antiepileptic drugs: generic versus
branded treatments.  Lancet Neurol 2007, 6(5):465-468.
4. Assessment: generic substitution for antiepileptic medica-
tion. Report of the Therapeutics and Technology Assess-
ment Subcommittee of the American Academy of
Neurology.  Neurology 1990, 40(11):1641-1643.
5. Jobst BC, Holmes GL: Prescribing antiepileptic drugs: should
patients be switched on the basis of cost?  CNS Drugs 2004,
18(10):617-628.
6. Berg MJ, Gross RA: Physicians and patients percive that
generic drug substitution of antiepileptic drugs can cause
breakthrough seizures: results from a US survey.  Epilepsia
2006, 47(Suppl 4):155.
7. Berg MJ, Gross RA, Tomaszewski KJ, Zingaro WM, Haskins LS:
Generic substitution in the treatment of epilepsy: case evi-
dence of breakthrough seizures.  Neurology 2008, 71(7):525-530.
8. Guberman A, Corman C: Generic substitution for brand name
antiepileptic drugs: a survey.  Can J Neurol Sci 2000, 27(1):37-43.
9. Haskins LS, Tomaszewski KJ, Crawford P: Patient and physician
reactions to generic antiepileptic substitution in the treat-
ment of epilepsy.  Epilepsy Behav 2005, 7(1):98-105.
10. Wilner AN: Therapeutic equivalency of generic antiepileptic
drugs: results of a survey.  Epilepsy Behav 2004, 5(6):995-998.
11. National Association of Boards of Pharmacy: Survey of pharmacy
law.  Mount Prospect, IL; 2006. 
12. Berg MJ: What's the problem with generic antiepileptic
drugs?: a call to action.  Neurology 2007, 68(16):1245-1246.
13. Borgheini G: The bioequivalence and therapeutic efficacy of
generic versus brand-name psychoactive drugs.  Clin Ther
2003, 25(6):1578-1592.
14. Crawford P, Feely M, Guberman A, Kramer G: Are there potential
problems with generic substitution of antiepileptic drugs? A
review of issues.  Seizure 2006, 15(3):165-176.
15. Danish Medicines Agency Guidelines and Forms   [http://
www.dkma.dk/1024/visUKLSArtikel.asp?artikelID=1586]
16. Wolf P: Political Campaign in Denmark.  Epilepsia 2007,
49(Suppl 7):6.
17. Nielsen KA, Dahl M, Tommerup E, Wolf P: Comparative daily
profiles with different preparations of lamotrigine: a pilot
investigation.  Epilepsy Behav 2008, 13(1):127-130.
18. Besag FM: Is generic prescribing acceptable in epilepsy?  Drug
Saf 2000, 23(3):173-182.
19. Berg MJ, Gross RA, Haskins LS, Zingaro WM, Tomaszewski KJ:
Generic substitution in the treatment of epilepsy: Patient
and physician perceptions.  Epilepsy Behav 2008, 13(4):693-699.
20. Hartley R, Aleksandrowicz J, Ng PC, McLain B, Bowmer CJ, Forsythe
WI: Breakthrough seizures with generic carbamazepine: a
consequence of poorer bioavailability?  Br J Clin Pract 1990,
44(7):270-273.
21. MacDonald JT: Breakthrough seizure following substitution of
Depakene capsules (Abbott) with a generic product.  Neurol-
ogy 1987, 37(12):1885.
22. Meyer MC, Straughn AB: Biopharmaceutical factors in seizure
control and drug toxicity.  Am J Hosp Pharm 1993, 50(12 Suppl
5):S17-22.
23. Bialer M: Generic products of antiepileptic drugs (AEDs): is it
an issue?  Epilepsia 2007, 48(10):1825-1832.
24. LeLorier J, Duh MS, Paradis PE, Lefebvre P, Weiner J, Manjunath R,
Sheehy O: Clinical consequences of generic substitution of
lamotrigine for patients with epilepsy.  Neurology 2008, 70(22
Pt 2):2179-2186.
25. Privitera MD: Generic antiepileptic drugs: current controver-
sies and future directions.  Epilepsy Currents 2008, 8(5):113-117.
26. Papsdorf TB, Ablah E, Ram S, Sadler T, Liow K: Patient perception
of generic antiepileptic drugs in the Midwestern United
States.  Epilepsy Behav 2008 in press.
27. Kramer G, Steinhoff BJ, Feucht M, Pfafflin M, May TW: Experience
with generic drugs in epilepsy patients: an electronic survey
of members of the German, Austrian and Swiss branches of
the ILAE.  Epilepsia 2007, 48(3):609-611.
28. Liow K, Barkley GL, Pollard JR, Harden CL, Bazil CW: Position
statement on the coverage of anticonvulsant drugs for the
treatment of epilepsy.  Neurology 2007, 68(16):1249-1250.
29. Perucca E, Albani F, Capovilla G, Bernardina BD, Michelucci R, Zac-
cara G: Recommendations of the Italian League against Epi-
lepsy working group on generic products of antiepileptic
drugs.  Epilepsia 2006, 47(Suppl 5):16-20.
30. Feely M, Crawford P, Kramer G, Guberman A: Risk management
in epilepsy: generic substitution and continuity of supply.  The
European Journal of Hospital Pharmacy Science 2005,
68(16):1249-1250.
31. Wyllie E, Pippenger CE, Rothner AD: Increased seizure fre-
quency with generic primidone.  JAMA 1987, 258(9):1216-1217.
32. Mikati M, Bassett N, Schachter S: Double-blind randomized study
comparing brand-name and generic phenytoin mono-
therapy.  Epilepsia 1992, 33(2):359-365.
33. Oles KS, Penry JK, Smith LD, Anderson RL, Dean JC, Riela AR: Ther-
apeutic bioequivalency study of brand name versus generic
carbamazepine.  Neurology 1992, 42(6):1147-1153.
34. Andermann F, Duh MS, Gosselin A, Paradis PE: Compulsory
generic switching of antiepileptic drugs: high switchback
rates to branded compounds compared with other drug
classes.  Epilepsia 2007, 48(3):464-469.
35. Dilorio C, Faherty B, Manteuffel B: Learning needs of persons
with epilepsy: a comparison of perceptions of persons with
epilepsy, nurses and physicians.  J Neurosci Nurs 1993,
25(1):22-29.
36. Lowes R: Patient-centered care for better patient adherence.
Fam Pract Manag 1998, 5(3):46-47. 51-44, 57
37. Schachter SC: Antiepileptic drug therapy: general treatment
principles and application for special patient populations.
Epilepsia 1999, 40(Suppl 9):S20-25.
38. Schachter SC: Epilepsy: Quality of Life and Cost of Care.  Epi-
lepsy Behav 2000, 1(2):120-127.
39. Busch RL: Generic carbamazepine and erythema multiforme:
generic-drug nonequivalency.  N Engl J Med 1989,
321(10):692-693.
40. Sachdeo RC, Belendiuk G: Generic versus branded car-
bamazepine.  Lancet 1987, 1(8547):1432.
41. Hovinga CA, Asato MR, Manjunath R, Wheless JW, Phelps SJ, Sheth
RD, Pina-Garza JE, Zingaro WM, Haskins LS: Association of non-
adherence to antiepileptic drugs and seizures, quality of life,
and productivity: survey of patients with epilepsy and physi-
cians.  Epilepsy Behav 2008, 13(2):316-322.
42. UCB Compliance Survey: Analysis and Takeaways.  Con-
ducted by Rosetta; 2008. 
43. Wolf P: Should newly diagnosed epilepsy be treated with
generics?  Nat Clin Pract Neurol 2008, 4(4):176-177.
44. AED and Continuity of Supply: Consideration for Patients.
Conducted by UCB, Inc.; Transcripts from Patient Forum held March
30, 2008, Washington, D.C. 
45. The President's Advisory Commission on Consumer Protection and
Quality in the Health Care Industry: Consumer Bill of Rights and
Responsibilities. Report to the President of the United
States.  Washington, DC: The President's Advisory Commission on
Consumer Protection and Quality in the Health Care Industry; 1997. 
46. Sipkoff M: The epilepsy battle in the war between brands and
generics.  Manag Care 2008, 17(3):24-27.
47. National Association of Boards of Pharmacy: Survey of Pharmacy
Laws. XIX.  Drug product selection laws 2006.Page 9 of 10
(page number not for citation purposes)
BMC Neurology 2009, 9:11 http://www.biomedcentral.com/1471-2377/9/11Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
48. Christensen TP, Kirking DM, Ascione FJ, Welage LS, Gaither CA:
Drug product selection: legal issues.  J Am Pharm Assoc (Wash)
2001, 41(6):868-874.
49. Vivian JC: Generic-Substitution Laws.  US Pharmacist 2008,
33(6):30-34.
50. Cassell DK: Should generic substitution of antiepileptic drugs
be restricted?  Drug Topics Suppl 2007.
51. Argumosa A, Herranz JL: The clinical and economic impact of
generic drugs in the treatment of epilepsy.  Rev Neurol 2005,
41(1):45-49.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2377/9/11/prepubPage 10 of 10
(page number not for citation purposes)
